Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Intercept Pharma Shares Rise on FDA Acceptance of NDA for Liver Fibrosis Treatment

Shares of Intercept Pharmaceuticals rose today after the company reported that the U.S. Food and Drug Administration accepted its NDA for obeticholic acid (OCA) for the treatment of liver fibrosis due to NASH and granted priority review status. This morning biopharmac...
Streetwise Reports | November 27, 2019 |

Biopharma Has Three 2020 Shots on Goal in Pediatric Liver Diseases

The events in that trio are presented in a ROTH Capital Partners report. In a Feb. 3 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that Albireo Pharma Inc. (ALBO:NASDAQ) plans to launch three clinical trials this year in the same num...
Streetwise Reports | February 10, 2020 |

FDA Grants Breakthrough Status to Biopharma's Lead Candidate for Liver Disease

The California firm's most advanced asset is advancing through Phase 2b, according to a ROTH Capital Partners report. In a Feb. 19 research note, analyst Yasmeen Rahimi reported that CymaBay Therapeutics Inc. (CBAY:NASDAQ) is having a strong Q1/19 with respect to cont...
Streetwise Reports | February 26, 2019 |

June 17th 2020, Crypto Chartbook: Failure equals big money

Failure equals big money If that be the case we’d be all rich trading the markets. No, what we are referring here to is pattern failure. Chart patterns have probabilities of how often they work. Most bet in favor of the favorable outcome of such patterns. ...
Korbinian Koller | June 17, 2020 |

Beware the Feint

Precious metals expert Michael Ballanger looks at the recent run-up in gold and reveals his recent trades. I am so confused tonight that I had to crowbar the booze cabinet in order to calm my scrambled soul and ease the pain in my pseudo-analytical chest. Th...
Streetwise Reports | June 26, 2019 |

Silver: The HARD Look

In this week's commentary, I am going to respond to the rash of end-of-the-world emails and terror-stricken texts that bombarded me after the BLS reported a better-than-expected Non-Farm Payrolls number Friday that sent stocks screaming higher and the precious metals in...
Streetwise Reports | December 11, 2019 |

Biopharma Reports Consistent 'Phase 2 Liver Fat (NASH and NAFLD) Results'

The new data are reviewed and updates are provided on Can-Fite BioPharma's other clinical studies, including one for COVID-19, in this Dawson James research report. In an April 20 research note, Dawson James analyst Jason Kolbert wrote that results from Can...
Streetwise Reports | April 23, 2020 |

NGM Biopharma Shares Rise on Positive Topline Data from Phase 2 NASH Trial

Shares of NGM Biopharmaceuticals reached a new 52-week intraday high price after the company posted positive topline data from Cohort 4 of its Phase 2 study of aldafermin in NASH Patients. On a day when world financial markets traded lower across the board, ...
Streetwise Reports | February 25, 2020 |

Shares Rise as The Medicines Company Reports Positive Topline Results...

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hype...
Streetwise Reports | September 26, 2019 |

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study

Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients. Clinical-stage biotechnology...
Streetwise Reports | July 2, 2020 |
1 2 3 4 5 6 7 8 9 10 ...